Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
CRNX Stock Chart & Stats
$39.96
-$0.61(-1.22%)
At close: 4:00 PM EST
$39.96
-$0.61(-1.22%)
Day’s Range― - ―
52-Week Range$24.10 - $57.99
Previous CloseN/A
Volume214.21K
Average Volume (3M)1.15M
Market Cap
$4.18B
Enterprise Value$4.13B
Total Cash (Recent Filing)$1.03B
Total Debt (Recent Filing)$48.54M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
May 07, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding104,705,330
10 Day Avg. Volume1,089,140
30 Day Avg. Volume1,145,276
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)4.41
Price to Sales (P/S)568.91
P/FCF Ratio-11.41
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue762.18
Enterprise Value/Gross Profit702.67
Enterprise Value/Ebitda-8.23
Forecast
1Y Price Target
$86.71Price Target Upside116.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.77
Revenue Forecast (FY)$62.05M
Bulls Say, Bears Say
Bulls Say
Clinical Development DesignA seamless Phase 2/3 trial design for atumelnant, combined with Phase 2 biomarker reductions and flexible steroid-tapering strategies, lowers development risk and strengthens late-stage success prospects.
Early Commercial TractionEarly commercial launch showed growing prescriber adoption across specialty and community settings plus favorable formulary placements, indicating momentum that could bolster sales as the launch scales.
Regulatory ApprovalA positive opinion from the European medicines committee recommending marketing authorization for Palsonify supports a credible path to European approval and expands potential market reach.
Bears Say
Financial PositionHigh cash burn and limited cash runway raise the prospect of needing additional financing, which could dilute shareholders and create execution risk.
International Commercialization UncertaintyUnclear plans for ex‑US commercialization and limited disclosure on international strategy make geographic expansion and revenue diversification uncertain.
Provider And Patient Adoption BarriersCost barriers and insufficient provider and patient education may limit uptake, while a potentially lumpy launch cadence reduces near-term revenue predictability.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $24.10 and its highest was $57.99 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Crinetics Pharmaceuticals’s market cap is $4.18B.
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is May 07, 2026 which is in 28 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on Feb 26, 2026. The company reported -$1.29 earnings per share for the quarter, beating the consensus estimate of -$1.348 by $0.058.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -1.21.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 104,705,330 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$1.29 in its last earnings report, beating expectations of -$1.348. Following the earnings report the stock price went down -6.036%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Currently, no hedge funds are holding shares in CRNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crinetics Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.71 (116.99% Upside)
$86.71 (116.99% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.4%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.20%
12-Months-Change
Fundamentals
Return on Equity
-41.46%
Trailing 12-Months
Asset Growth
-34.22%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
CRNX Company Deck
CRNX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple important positives: a commercially launched product showing early physician uptake and payer wins, strong clinical readouts and regulatory progress for late-stage programs (atumelnant and CRN09682), and a robust cash position (post-offering ~ $1.4B) with runway into 2030. Offsetting these are modest 2025 revenues relative to substantial R&D and SG&A spend, elevated 2026 operating expense guidance, and continued early-stage reimbursement and launch execution risks (≈50% Quickstart usage, uncertain conversion timings). On balance, the strengths—successful launch momentum, compelling clinical data, regulatory milestone, and a very strong balance sheet—outweigh the operational and near-term revenue challenges.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$86.71
▲(116.99% Upside)
Technical Analysis
Ligand Pharma
―
Ultragenyx Pharmaceutical
―
Apellis Pharmaceuticals
―
―
Kymera Therapeutics
―
Ownership Overview
1.98% Insiders
37.23% Mutual Funds
35.81% Other Institutional Investors
10.23% Public Companies and Individual Investors